# Labcorp Holdings Inc.  Share Price Target ‘$253.07’, now 11.8% Upside Potential

- Link: https://www.directorstalkinterviews.com/labcorp-holdings-inc.share-price-target-253.07-now-11.8-upside-potential/4121168179
- Published: 2024-08-13T13:21:07+01:00
- Author: Charlotte Edwards

**Labcorp Holdings Inc.** which can be found using ticker (LH) now have 14 confirmed
analysts covering the stock with the consensus suggesting a rating of ‘buy’. The
target price High/Low ranges between $277.00 and $210.00 with the average share 
target price sitting at $253.07. (at the time of writing). Given that the stocks
previous close was at $226.46 this is indicating there is a potential upside of 
11.8%. Also worth taking note is the 50 day moving average now sits at $208.35 while
the 200 day moving average is $212.40. The total market capitalization for the company
now stands at 18.75B. The price for the stock stands currently at: $223.34 USD

 The potential market cap would be $20,955,843,755 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of 41.51, revenue per share of $147.17
and a 4.08% return on assets.

Laboratory Corporation of America Holdings is a global life sciences company. The
Company provides information to help doctors, hospitals, pharmaceutical companies,
researchers, and patients make decisions. The Company’s segments include Labcorp
Diagnostics (Dx) and Labcorp Drug Development (DD). The Dx segment is an independent
clinical laboratory business. It offers a menu of frequently requested and specialty
diagnostic tests through an integrated network of primary and specialty laboratories
across the United States. In addition to diagnostic testing along with occupational
and wellness testing for employers and forensic DNA analysis, Dx segment also offers
a range of other testing services. The DD segment is a contract research organizations
business that provides end-to-end drug development services. The DD segment provides
these services predominantly to pharmaceutical, biotechnology and medical device
companies across the world. It serves clients in more than 100 countries.

Share on:
